



BIOFIL CHEMICALS & PHARMACEUTICALS LTD.

Regd. Office : 11/12, Sector-E, Sanwer Road, Industrial Area, Indore - 452 015. Fax : 0731-2723017
Tel. : 0731-2723016, 4066216 E-mail : biofilchemicals@yahoo.com / bcplcompliance@gmail.com
Factory : Plot No. 8, Sector - IV, Kheda Industrial Area, Pithampur Distt. Dhar (M.P.)

Admn. Office : B-12/B, Industrial Estate, Pologround, Indore - 452 015 (M.P.)
Tel. : 0731-2426700, 2426718, 2524003, Fax : 0731-2426726 • CIN : L24233MP1985PLC002709

Date: 11th November, 2020

| | |
|--|--|
| To, The Company Secretary, Corporate Compliance Department The National Stock Exchange of India Limited Bandra Kurla Complex, Mumbai | To, The Company Secretary Corporate Compliance Department BSE Limited Dalal Street, P.J. Tower, Mumbai |
|--|--|

Subject: Submission of Un-Audited Financial Result for the quarter and half year ended on 30th September, 2020 in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015.

Ref: BIOFIL CHEMICALS & PHARMACEUTICALS LIMITED (BSE Scrip Code: 524396; NSE Symbol: BIOFILCHEM, ISIN: INE829A01014)

Dear Sir/Madam

In compliance with Regulation 33 of SEBI (LODR) Regulations, 2015, we are pleased to submit Un-audited Financial Results for the quarter and half year ended 30th September, 2020 duly approved by the Board at its meeting held on today i.e. on 11th November, 2020 at the registered office of the Company along with Limited Review Report given by the Statutory Auditors of the Company, as required under the above said Regulations. Copy of Unaudited Financial Results along with Limited Review Report is enclosed with this letter.

Further, pursuant to Regulation 33 (f) and (g) of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015, we have also enclosed Statement of Assets and Liabilities and Cash Flow Statement for the half year ended on 30th September 2020.

Further, copy of Un-Audited Financial Statements and Limited Review Report shall also be submitted in XBRL mode (Excel Template provided by Exchange) within 24 hours from the conclusion of Board Meeting.

The aforesaid results will be published in one Hindi (vernacular) and widely circulated English Newspaper. The Results shall also be uploaded on website of Stock Exchanges i.e. www.bseindia.com and www.nseindia.com and on the website of the Company at www.biofilgroup.net.

You are requested to take on record the above said financial results for your reference and record.

Yours Faithfully

For Biofil Chemicals and Pharmaceuticals Limited

Ramesh Shah
Managing Director
(DIN 00028819)



Biofil Chemicals and Pharmaceuticals Limited

Registered Office: 11/12, Sector-'E' Sanwer Road, Industrial Area, Indore (M.P.)

CIN L24233MP1985PLC002709

Email Id: bcplcompliance@gmail.com Phone No. 0731-2426718, 2723016-17 Website: www.biofilgroup.net

Statement of Unaudited Financial Results for the quarter and Half Year ended 30th September 2020

(Amount in Lakhs except EPS)

Statement of Unaudited Financial Results for the quarter and Half Year ended 30th September 2020

| Sr No. | Particulars | Quarter Ended | | | Half Year Ended | | Previous Year Ended |
|--------|--|--------------------------|--------------------------|--|--|---|--------------------------|
| | | 3 Month Ended 30/09/2020 | 3 Month Ended 30/06/2020 | Corresponding 3 months ended in the previous year (30/09/2019) | Year to date figures for current period ended (30/09/2020) | Year to date figures for the previous year ended (30/09/2019) | Year ended March 31 2020 |
| | | Unaudited | Unaudited | Unaudited | Unaudited | Unaudited | Audited |
| I | Revenue from Operation | 1601.86 | 230.11 | 1162.88 | 1831.97 | 1322.29 | 2969.02 |
| II | Other Income | 14.59 | 63.62 | 3.36 | 78.21 | 4.47 | 17.15 |
| III | Total Revenue (I + II) | 1616.45 | 293.72 | 1166.24 | 1910.18 | 1326.77 | 2986.17 |
| IV | Expenses | | | | | | |
| | (a) Cost of materials consumed | 138.95 | 139.65 | 97.60 | 278.60 | 184.27 | 405.66 |
| | (b) Purchases of stock-in-trade | 75.45 | 1209.89 | 2119.94 | 1285.35 | 2144.97 | 2159.45 |
| | (c) Changes in inventories of finished goods, work-in-progress and stock-in-trade | 1,252.53 | (1122.16) | (1205.14) | 130.37 | (1,219.09) | (34.23) |
| | (d) Employee benefits expense | 23.25 | 16.75 | 21.46 | 40.00 | 40.43 | 86.34 |
| | (e) Finance Cost | 2.00 | 2.45 | 3.27 | 4.45 | 6.86 | 12.24 |
| | (f) Depreciation and Amortisation Expense | 10.88 | 10.21 | 9.45 | 21.09 | 18.58 | 40.83 |
| | (g) Other expenses | 20.69 | 15.27 | 40.53 | 35.96 | 67.72 | 169.47 |
| | Total expenses (IV) | 1523.74 | 272.06 | 1087.11 | 1795.80 | 1243.75 | 2839.76 |
| V | Profit/ (Loss) before exceptional items and tax (III-IV) | 92.71 | 21.66 | 79.13 | 114.37 | 83.02 | 146.41 |
| VI | Exceptional Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| VII | Profit/ (Loss) before tax (V - VI) | 92.71 | 21.66 | 79.13 | 114.37 | 83.02 | 146.41 |
| VIII | Tax expense: | | | | | | |
| | (1) Current tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 25.69 |
| | (2) Deferred tax Credit/(Charge) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| IX | Profit/(Loss) for the period from continuing operation (VII-VIII) | 92.71 | 21.66 | 79.13 | 114.37 | 83.02 | 120.72 |
| X | Profit/(Loss) from dis-continued operation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| XI | Tax expenses of discontinued operation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| XII | Profit/(Loss) from dis-continued operation after tax (X-XI) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| XIII | Profit/ (Loss) for the period (IX+XII) | 92.71 | 21.66 | 79.13 | 114.37 | 83.02 | 120.72 |
| XIV | Other Comprehensive Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| | A) (I) Items that will not be reclassified to Profit or Loss | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| | (II) Income Tax relating to items that will not be reclassified to Profit or Loss | | | | 0.00 | | |
| | B) (i) Items that will be reclassified to Profit or Loss | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| | (II) Income Tax relating to items that will be reclassified to Profit or Loss | | | | 0.00 | | |
| | c) Other Comprehensive Income (net of tax) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.62 |
| XV | Total Comprehensive Income for the period (XIII + XIV) (Comprising Profit or Loss and other Comprehensive income for the period) | 92.71 | 21.66 | 79.13 | 114.37 | 83.02 | 123.35 |
| XVI | Paid-Up equity share capital (face value of Rs 10/- each) | 1627.38 | 1627.38 | 1627.38 | 1627.38 | 1627.38 | 1627.38 |
| XVII | Reserves (Excluding Revaluation Reserve) | | | | | | -515.27 |
| XVIII | Earnings per equity shares (for continuing operation): | | | | | | |
| | (1) Basic (Rs) | 0.57 | 0.13 | 0.49 | 0.70 | 0.51 | 0.76 |
| | (2) Diluted (Rs) | 0.57 | 0.13 | 0.49 | 0.70 | 0.51 | 0.76 |

Biofil Chemicals and Pharmaceuticals Limited

Registered Office: 11/12, Sector-'E' Sanwer Road, Industrial Area, Indore (M.P.)

CIN L24233MP1985PLC002709

Email Id:bcplcompliance@gmail.com Phone No. 0731-2426718, 2723016-17

Segmentwise Revenue, Results and Capital Employed for quarter ended 30th September-2020

(Amount in Lakhs)

| S.No. | Segment Revenue | Quarter Ended | | | | Year Ended | |
|-------|---|------------------|-------------------|------------------|------------------|------------------|------------------|
| | | Sep 30 , 2020 | June 30 , 2020 | Sep 30 , 2019 | Sep 30 , 2020 | Sep 30 , 2019 | 31 March 2020 |
| | | Reviewed | Reviewed | Reviewed | Reviewed | Audited | Audited |
| 1 | Segment Revenue | | | | | | |
| | Pharma Unit | 1,384.61 | 24.75 | 998.46 | 1,409.36 | 1,054.05 | 2,436.17 |
| | Chemicals Division | 217.25 | 205.35 | 164.42 | 422.61 | 268.24 | 532.85 |
| | Plastic Division | | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| | Other | 14.59 | 63.62 | 2.32 | 78.21 | 3.43 | 19.77 |
| | Gross Turnover | 1,616.45 | 293.72 | 1,165.20 | 1,910.18 | 1,325.73 | 2,988.79 |
| 2 | Segment Results | | | | | | |
| | Pharma Unit | 64.19 | -9.92 | 67.82 | 54.27 | 75.88 | 91.41 |
| | Chemicals Division | 30.51 | 34.01 | 14.57 | 64.53 | 17.53 | 67.60 |
| | Plastic Division | 0.00 | 0.00 | -1.06 | 0.00 | -4.63 | -6.81 |
| | Other | 0.00 | 0.00 | | 0.00 | 0.00 | 0.00 |
| | Total Segment Profit Before Tax | 94.71 | 24.09 | 81.33 | 118.80 | 88.79 | 152.20 |
| | Interest Income | 0.00 | 0.00 | 1.04 | 0.00 | 1.04 | 2.16 |
| | Interest Expenses | 2.00 | 2.44 | 3.25 | 4.43 | 6.81 | 5.33 |
| | Other Unallocable Income net of Expenditure | | | | | | |
| | Profit Before Tax | 92.71 | 21.66 | 79.13 | 114.37 | 83.02 | 149.03 |
| | Provision for current tax | 0.00 | 0.00 | | 0.00 | 0.00 | 24.88 |
| | Item Related Earlier Year | 0.00 | 0.00 | | 0.00 | 0.00 | 0.81 |
| | Profit After Tax | 92.71 | 21.66 | | 114.37 | 83.02 | 123.35 |
| 3 | Capital Employed | | | | | | |
| | Segment Assets (A) | | | | | | |
| | Pharma Division | 2,203.60 | 2,125.11 | 3,424.07 | 2,203.60 | 3,424.07 | 3,017.03 |
| | Chemicals Division | 1,250.61 | 1,228.95 | 1,073.39 | 1,250.61 | 1,073.39 | 1,219.47 |
| | Plastic Division | 0.00 | 0.00 | 51.11 | 0.00 | 51.11 | 0.00 |
| | Other | | | | | | |
| | Total (A) | 3,454.22 | 3,354.06 | 4,548.57 | 3,454.22 | 4,548.57 | 4,236.49 |
| | Segment Liabilities (B) | | | | | | |
| | Pharma Division | 1,609.82 | 1,519.12 | 2,762.38 | 1,609.82 | 2,762.38 | 2,404.93 |
| | Chemicals Division | 212.52 | 254.79 | 175.91 | 212.52 | 175.91 | 343.24 |
| | Plastic Division | 0.00 | 0.00 | 143.71 | 0.00 | 143.71 | 0.00 |
| | Other | | | | | 0.00 | |
| | Total (B) | 1,822.34 | 1,773.91 | 3,082.00 | 1,822.34 | 3,082.00 | 2,748.18 |
| | Total Capital Employed (Segment Assets- Segment Liabilities) | | | | | | |
| | Pharma Division | 593.78 | 605.99 | 661.69 | 593.78 | 661.69 | 612.09 |
| | Chemicals Division | 1,038.09 | 974.16 | 897.48 | 1,038.09 | 897.48 | 876.22 |
| | Plastic Division | 0.00 | 0.00 | -92.60 | 0.00 | -92.60 | 0.00 |
| | Other | | | | | | 0.00 |
| | Total Capital Employed (Segment Assets- Segment Liabilities) | 1,631.87 | 1,580.15 | 1,466.57 | 1,631.87 | 1,466.57 | 1,488.32 |

DATE : 11/11/2020
PLACE : INDORE

BIOFIL CHEMICALS AND PHARMACEUTICALS LTD.

RAMESH SHAH
MANAGING DIRECTOR
DIN: 00028819

1 The above Un-Audited financial results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on 11th November, 2020. The Unaudited interim financial results for the quarter and half year ended 30th September, 2020 have been subjected to limited review by the statutory auditors, who have expressed an unmodified opinion.

2 The financial results of the Company have been prepared in accordance with the recognition and measurement principles laid down in the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and the other accounting principles generally accepted in India.

3 The figures of the previous period / year have been re-stated/ re-grouped / re-arranged/ reclassified and / or recasted wherever found necessary.

4 The Company has reported segment wise information as per Indian Accounting Standard (Ind AS-108). The Operations of the Company are conducted within India, there is no separate reportable geographical segment and the company reported the following business segments

- a. Pharma Product
- b. Chemicals Division

5 The aforesaid un-audited financial Results will be uploaded on the Company's website www.biofilgroup.net and will also be available on the websites of the Stock exchanges i.e. www.bseindia.com and www.nseindia.com for the benefit of shareholders and investors

6 The Earning Per Shares (Basic and Diluted) for the interim period have not been annualized.

Date : 11-11-2020

Place : Indore

For Biofil Chemicals & Pharmaceuticals Limited



RAMESH SHAH
MANAGING DIRECTOR
(DIN: 00028819)



Biofil Chemicals and Pharmaceuticals Limited

Registered Office: 11/12, Sector-'E' Sanwer Road, Industrial Area, Indore (M.P.)

CIN L24233MP1985PLC002709

Email Id:bcplcompliance@gmail.com Phone No. 0731-2426718, 2723016-17

Segmentwise Revenue, Results and Capital Employed for quarter and Half year ended 30th September-2020

(Amount in Lakhs)

| S.No. | Segment Revenue | Quarter Ended | | Half Year Ended | | Year Ended |
|-------|---|------------------|------------------|------------------|------------------|------------------|
| | | Sep 30 , 2020 | Sep 30 , 2019 | Sep 30 , 2020 | Sep 30 , 2019 | 31 March 2020 |
| | | Reviewed | Reviewed | Reviewed | Reviewed | Audited |
| 1 | Segment Revenue | | | | | |
| | Pharma Unit | 1,384.61 | 998.46 | 1,409.36 | 1,054.05 | 2,436.17 |
| | Chemicals Division | 217.25 | 164.42 | 422.61 | 268.24 | 532.85 |
| | Plastic Division | | 0.00 | 0.00 | 0.00 | 0.00 |
| | Other | 14.59 | 2.32 | 78.21 | 3.43 | 19.77 |
| | Gross Turnover | 1,616.45 | 1,165.20 | 1,910.18 | 1,325.73 | 2,988.79 |
| 2 | Segment Results | | | | | |
| | Pharma Unit | 64.19 | 67.82 | 54.27 | 75.88 | 91.41 |
| | Chemicals Division | 30.51 | 14.57 | 64.53 | 17.53 | 67.60 |
| | Plastic Division | 0.00 | -1.06 | 0.00 | -4.63 | -6.81 |
| | Other | 0.00 | | 0.00 | 0.00 | 0.00 |
| | Total Segment Profit Before Tax | 94.71 | 81.33 | 118.80 | 88.79 | 152.20 |
| | Interest Income | 0.00 | 1.04 | 0.00 | 1.04 | 2.16 |
| | Interest Expenses | 2.00 | 3.25 | 4.43 | 6.81 | 5.33 |
| | Other Unallocable Income net of Expenditure | | | | | |
| | Profit Before Tax | 92.71 | 79.13 | 114.37 | 83.02 | 149.03 |
| | Provision for current tax | 0.00 | | 0.00 | 0.00 | 24.88 |
| | Item Related Earlier Year | 0.00 | | 0.00 | 0.00 | 0.81 |
| | Profit After Tax | 92.71 | | 114.37 | 83.02 | 123.35 |
| 3 | Capital Employed | | | | | |
| | Segment Assets (A) | | | | | |
| | Pharma Division | 2,203.60 | 3,424.07 | 2,203.60 | 3,424.07 | 3,017.03 |
| | Chemicals Division | 1,250.61 | 1,073.39 | 1,250.61 | 1,073.39 | 1,219.47 |
| | Plastic Division | 0.00 | 51.11 | 0.00 | 51.11 | 0.00 |
| | Other | | | | | |
| | Total (A) | 3,454.22 | 4,548.57 | 3,454.22 | 4,548.57 | 4,236.49 |
| | Segment Liabilities (B) | | | | | |
| | Pharma Division | 1,609.82 | 2,762.38 | 1,609.82 | 2,762.38 | 2,404.93 |
| | Chemicals Division | 212.52 | 175.91 | 212.52 | 175.91 | 343.24 |
| | Plastic Division | 0.00 | 143.71 | 0.00 | 143.71 | 0.00 |
| | Other | | | | 0.00 | |
| | Total (B) | 1,822.34 | 3,082.00 | 1,822.34 | 3,082.00 | 2,748.18 |
| | Total Capital Employed (Segment Assets- Segment Liabilities) | | | | | |
| | Pharma Division | 593.78 | 661.69 | 593.78 | 661.69 | 612.09 |
| | Chemicals Division | 1,038.09 | 897.48 | 1,038.09 | 897.48 | 876.22 |
| | Plastic Division | 0.00 | -92.60 | 0.00 | -92.60 | 0.00 |
| | Other | | | | | 0.00 |
| | Total Capital Employed (Segment Assets- Segment Liabilities) | 1,631.87 | 1,466.57 | 1,631.87 | 1,466.57 | 1,488.32 |

DATE : 11/11/2020

PLACE: INDORE

BIOFIL CHEMICALS AND PHARMACEUTICALS LTD.

Ramesh Shah

RAMESH SHAH

MANAGING DIRECTOR

DIN: 00028819

Biofil Chemicals and Pharmaceuticals Limited

Registered Office: 11/12, Sector-'E' Sanwer Road, Industrial Area, Indore (M.P.)

CIN L24233MP1985PLC002709

Email Id:bcplcompliance@gmail.com Phone No. 0731-2426718, 2723016-17 Website: www.biofilgroup.net

Statement of cash flows for the year half year ended 30th Sept 2020


(Amount in Lakhs)

| Particulars | HALF YEAR ENDED ON 30.09.20 | HALF YEAR ENDED ON 30.09.19 |
|---|-----------------------------------|-----------------------------------|
| Cash flow from operating activities | | |
| Profit before tax | 114.37 | 83.02 |
| Adjustments to reconcile profit before tax to net cash used in operating activities | | |
| Depreciation of property, plant and equipment | 21.09 | 18.58 |
| Finance cost | 4.45 | 6.86 |
| Impact Considered in OCI | | |
| Net (gain)/ loss on derivative contracts on account of Ind AS adjustments | | |
| Provision for doubtful advances/ debts | | |
| | 139.91 | 108.46 |
| Working capital adjustments | | |
| Increase/ (Decrease) in Inventory | 59.12 | (1240.63) |
| (Increase)/ Decrease in Trade Receivable | 748.96 | (669.36) |
| (Increase)/ Decrease in other current assets | (0.42) | (202.27) |
| Increase/ (Decrease) in trade payables | (890.89) | 2069.58 |
| Increase/ (Decrease) in other financial liabilities | 4.06 | 0.00 |
| Increase/ (Decrease) in other liabilities | 0.00 | (8.74) |
| Cash generated from operations | 60.75 | 57.04 |
| Current tax assets | 0.00 | (11.60) |
| Net cash flows from operating activities | 60.75 | 45.44 |
| Cash flow from investing activities | | |
| Payment for purchase and construction of property, plant and equipment | 13.20 | 11.33 |
| Proceeds from sale of property, plant and equipment | 0.00 | 0.00 |
| (Increase)/ Decrease in other bank balances | | |
| Interest received | | |
| Net cash flows from investing activities | 13.20 | 11.33 |
| Cash flow from financing activities | | |
| Increase/ (decrease) in Borrowings | (38.99) | (20.02) |
| Deemed Investment by Holding Company | | |
| Finance cost | (4.45) | (6.86) |
| Net cash flows from financing activities | (43.44) | (26.88) |
| Net increase / (decrease) in cash and cash equivalents | 4.11 | 7.23 |
| Cash and cash equivalents at the beginning of the year | 25.60 | 13.62 |
| Cash and cash equivalents at the end of the year | 29.71 | 20.85 |
| Increase / (Decrease) in cash and cash equivalents | 4.11 | 7.23 |

Date: 11/11/2020

Place: INDORE

BIOFIL CHEMICALS AND PHARMACEUTICALS LTD.



RAMESH SHAH
MANAGING DIRECTOR
(DIN 00028819)

Biofil Chemicals and Pharmaceuticals Limited

Registered Office: 11/12, Sector-'E' Sanwer Road, Industrial Area, Indore (M.P.)

CIN L24233MP1985PLC002709

Email Id:bcplcompliance@gmail.com Phone No. 0731-2426718, 2723016-17


UN-AUDITED STATEMENT OF ASSETS AND LIABILITIES AS AT 30-09-2020

| | | (Amount in Lakhs) | |
|---|------------------|-------------------|--|
| Particulars | As at 30/09/2020 | As at 31/03/2020 | |
| A ASSETS | | | |
| 1 Non-current assets: | | | |
| (a) Property, Plant & Equipment | 1001.38 | 1,009.26 | |
| (b) Capital work in Progress | | - | |
| (c) Investment Property | | - | |
| (d) Goodwill | | - | |
| (e) Other Intangible assets | | - | |
| (f) Intangible Assets under development | | - | |
| (g) Biological Assets other than bearer plants | | - | |
| (h) Financial Assets: | | - | |
| i. Investments | | - | |
| ii. Trade receivables | | - | |
| iii. Loans | | - | |
| (i) Deferred tax assets (net) | | - | |
| (j) Other Non- Current Assets | | - | |
| Sub-total - Non-current assets | 1,001.38 | 1,009.26 | |
| 2 Current assets | | | |
| (a) Inventories | 110.09 | 169.21 | |
| (b) Financial Assets: | | | |
| (i) Investment | | - | |
| (ii) Trade receivables | 2221.90 | 2,970.86 | |
| (iii) Cash and cash equivalents | 24.45 | 17.76 | |
| (iv) Bank balances other than (iii) above | 5.26 | 7.84 | |
| (v) Loans | | - | |
| (vi) Others (to be specified) | | - | |
| (c) Current Tax Assest (Net) | | - | |
| (d) Other Currents Assets | 61.96 | 61.54 | |
| Sub-total - Current assets | 2,423.66 | 3,227.22 | |
| TOTAL - ASSETS | 3,425.05 | 4,236.48 | |
| B EQUITY AND LIABILITIES | | | |
| 1 Equity | | | |
| (i) Equity Share Capital | 1627.38 | 1,627.38 | |
| (ii) Other Entity | (24.67) | (139.06) | |
| Sub-total- Equity | 1602.71 | 1,488.32 | |
| 2 Liabilities | | | |
| Non-current Liabilities : | | | |
| a. Financial Liabilities | | | |
| (i) Borrowings | | | |
| (ii) Trade Payable | | | |
| (a) total outstanding dues of micro enterprises and small enterprises; and | | | |
| (b) total outstanding dues of creditors other than micro enterprises and small Enterprises. | | | |
| (iii) other Financial Liabilities (other than those specified in item (b), to be specified) | | | |
| b. Provisions | | | |
| c. Deferred tax liabilities (net) | | | |
| d. Other Non-current Liabilities | | | |
| Sub-total - Non-current liabilities | 1,602.71 | 1,488.32 | |
| 3 Current liabilities | | | |
| a. Financial Liabilities | | | |
| (i) Borrowings | 80.21 | 119.20 | |
| (ii) Trade Payables :- | | | |
| (a) total outstanding dues of micro enterprises and small enterprises; and | | - | |
| (b) total outstanding dues of creditors other than micro enterprises and small Enterprises. | 1700.86 | 2,591.75 | |
| (iii) other Financial Liabilities [other than those specified in item (a)] | 16.39 | 12.32 | |
| b. Other Current Liabilities | | | |
| c. Provisions | 24.88 | 24.88 | |
| d. Current Tax Liabilities (Net) | | | |
| Sub-total - Current liabilities | 1,822.34 | 2,748.16 | |
| TOTAL - EQUITY AND LIABILITIES | 3,425.05 | 4,236.48 | |

Date: 11/11/2020

Place: INDORE

BIOFIL CHEMICALS AND PHARMACEUTICALS LTD.



RAMESH SHAH
MANAGING DIRECTOR
(DIN 00028819)



MAHESHWARI & GUPTA
Chartered Accountants

Limited Review Report
(Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements)

To
The Board of Directors
Biofil Chemicals and Pharmaceuticals Limited
Indore

Review report to **Biofil Chemicals and Pharmaceuticals Limited**

We have reviewed the accompanying statement of unaudited financial results of **Biofil Chemicals and Pharmaceuticals Limited** for the period ended 30th September 2020 being submitted by the Company pursuant to Regulation 33 SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including relevant circular issued by the SEBI from time to time. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with Indian Accounting Standard 34, Interim Financial Reporting (Ind As 34) prescribed under section 133 of Companies Act 2013 and generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as stated in paragraph 2 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion is not modified in respect of this matter.

Place: Indore
Date: 11.11.2020

For Maheshwari & Gupta
Chartered Accountant

CA Sunil Maheshwari
Partner
M No. 403346

UDIN: 20403346 AAAA/L1478